WO2006068953A3 - Antibodies directed to angiopoietin-2 and uses thereof - Google Patents

Antibodies directed to angiopoietin-2 and uses thereof Download PDF

Info

Publication number
WO2006068953A3
WO2006068953A3 PCT/US2005/045657 US2005045657W WO2006068953A3 WO 2006068953 A3 WO2006068953 A3 WO 2006068953A3 US 2005045657 W US2005045657 W US 2005045657W WO 2006068953 A3 WO2006068953 A3 WO 2006068953A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies directed
light chain
sequences
angiopoietin
heavy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/045657
Other languages
French (fr)
Other versions
WO2006068953A2 (en
Inventor
Larry L Green
Qing Zhou
Bruce A Keyt
Xiao-Dong Yang
Stephen Charles Emery
David C Blakey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36405885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006068953(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0519596-9A priority Critical patent/BRPI0519596B1/en
Priority to US11/793,720 priority patent/US20080267971A1/en
Priority to AU2005319382A priority patent/AU2005319382B2/en
Priority to PL05854387T priority patent/PL1838733T3/en
Priority to MX2007007484A priority patent/MX2007007484A/en
Priority to HK08103398.4A priority patent/HK1109409B/en
Priority to JP2007548333A priority patent/JP4884395B2/en
Priority to AT05854387T priority patent/ATE521638T1/en
Priority to NZ556029A priority patent/NZ556029A/en
Priority to EP20156190.9A priority patent/EP3699191A1/en
Priority to EP05854387A priority patent/EP1838733B1/en
Priority to CN200580048270.9A priority patent/CN101128483B/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to SI200531408T priority patent/SI1838733T1/en
Priority to CA 2595610 priority patent/CA2595610C/en
Priority to DK05854387T priority patent/DK1838733T3/en
Priority to HR20110859T priority patent/HRP20110859T1/en
Publication of WO2006068953A2 publication Critical patent/WO2006068953A2/en
Anticipated expiration legal-status Critical
Priority to NO20073192A priority patent/NO20073192L/en
Publication of WO2006068953A3 publication Critical patent/WO2006068953A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determining regions (CDR’s), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobin molecules and monoclonal antibodies.
PCT/US2005/045657 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof Ceased WO2006068953A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
HR20110859T HRP20110859T1 (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof
EP05854387A EP1838733B1 (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof
AU2005319382A AU2005319382B2 (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof
PL05854387T PL1838733T3 (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof
MX2007007484A MX2007007484A (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof.
HK08103398.4A HK1109409B (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof
JP2007548333A JP4884395B2 (en) 2004-12-21 2005-12-19 Antibodies against angiopoietin-2 and their use
AT05854387T ATE521638T1 (en) 2004-12-21 2005-12-19 ANTIBODIES DIRECTED AGAINST ANGIOPOIETIN-2 AND USES THEREOF
NZ556029A NZ556029A (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof
BRPI0519596-9A BRPI0519596B1 (en) 2004-12-21 2005-12-19 TARGETED BINDING AGENT, MONOCLONAL ANTIBODY THAT BINDS TO ANGIOPOIETIN-2, NUCLEIC ACID MOLECULE, VECTOR, E, TARGETED BINDING AGENT USE
CN200580048270.9A CN101128483B (en) 2004-12-21 2005-12-19 Angiopoietin-2 antibody and its application
US11/793,720 US20080267971A1 (en) 2004-12-21 2005-12-19 Antibodies Directed to Angiopoietin-2 and Uses Thereof
EP20156190.9A EP3699191A1 (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof
SI200531408T SI1838733T1 (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof
CA 2595610 CA2595610C (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof
DK05854387T DK1838733T3 (en) 2004-12-21 2005-12-19 Antibodies directed against angiopoietin-2 and uses thereof
NO20073192A NO20073192L (en) 2004-12-21 2007-06-22 Antibodies directed against angiopoietin-2 and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63835404P 2004-12-21 2004-12-21
US60/638,354 2004-12-21
US71128905P 2005-08-25 2005-08-25
US60/711,289 2005-08-25

Publications (2)

Publication Number Publication Date
WO2006068953A2 WO2006068953A2 (en) 2006-06-29
WO2006068953A3 true WO2006068953A3 (en) 2007-08-02

Family

ID=36405885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045657 Ceased WO2006068953A2 (en) 2004-12-21 2005-12-19 Antibodies directed to angiopoietin-2 and uses thereof

Country Status (26)

Country Link
US (5) US20080267971A1 (en)
EP (3) EP2284194A1 (en)
JP (2) JP4884395B2 (en)
KR (1) KR101017301B1 (en)
CN (2) CN101128483B (en)
AR (1) AR052065A1 (en)
AT (1) ATE521638T1 (en)
AU (1) AU2005319382B2 (en)
BR (1) BRPI0519596B1 (en)
CA (1) CA2595610C (en)
CY (1) CY1112909T1 (en)
DK (1) DK1838733T3 (en)
ES (1) ES2371083T3 (en)
HR (1) HRP20110859T1 (en)
MX (1) MX2007007484A (en)
NO (1) NO20073192L (en)
NZ (1) NZ556029A (en)
PL (1) PL1838733T3 (en)
PT (1) PT1838733E (en)
RS (1) RS52036B (en)
RU (1) RU2394839C2 (en)
SI (1) SI1838733T1 (en)
TW (1) TW200634027A (en)
UY (1) UY29288A1 (en)
WO (1) WO2006068953A2 (en)
ZA (1) ZA200705695B (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US9518131B2 (en) 2013-04-02 2016-12-13 Miltenyi Biotech Gmbh Generating metal ion binding proteins
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US9982036B2 (en) 2011-02-28 2018-05-29 Hoffmann-La Roche Inc. Dual FC antigen binding proteins
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US10138293B2 (en) 2007-12-21 2018-11-27 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
US10640555B2 (en) 2009-06-16 2020-05-05 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1278778A2 (en) * 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1962903B1 (en) * 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
ES2828739T3 (en) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Antibodies that bind to human protein tyrosine phosphatase beta (HPTP-beta) and their uses
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CL2007002668A1 (en) 2006-09-20 2008-05-09 Amgen Inc ANTIGEN UNION PROTEIN THAT JOINS THE HUMAN GLUCAGON RECEIVER; NUCLEIC ACID THAT CODIFIES IT; METHOD OF PRODUCTION; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT OR PREVENT TYPE 2 DIABETES.
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
ES2610474T3 (en) * 2007-01-11 2017-04-27 Michael Bacher Diagnosis and treatment of Alzheimer's disease and other neurodegenerative diseases causing dementia
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
KR101652125B1 (en) * 2007-09-26 2016-08-29 우드라이 파마 게엠베하 Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
US20110008804A1 (en) * 2007-11-05 2011-01-13 Kain Kevin C Angiopoietin-1 and -2 biomarkers for infectious diseases that compromise endothelial integrity
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
EA021967B1 (en) 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Antibody targeting through a modular recognition domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8507656B2 (en) * 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20110016959A (en) 2008-06-03 2011-02-18 아보트 러보러터리즈 Dual Variable Domain Immunoglobulins and Uses thereof
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
PE20141398A1 (en) 2008-07-16 2014-10-18 Inst Research In Biomedicine NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
AU2013202393B2 (en) * 2008-07-16 2015-01-22 Institute For Research In Biomedicine Human cytomegalovirus nuetralizing antibodies and use thereof
US9000131B2 (en) * 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
UA112050C2 (en) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі THERAPEUTIC COMPOSITION CONTAINING MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR (TFPI)
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
AU2016244220B2 (en) * 2008-12-23 2018-05-17 Amgen Inc. Human CGRP receptor binding proteins
JO3382B1 (en) * 2008-12-23 2019-03-13 Amgen Inc Human cgrp receptor binding antibodies
PT2385763T (en) * 2009-01-12 2018-07-13 Aerpio Therapeutics Inc Methods for treating vascular leak syndrome
JP2012521197A (en) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Carrier immunoglobulin and use thereof
WO2010129609A2 (en) * 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
MX337468B (en) 2009-06-18 2016-03-02 Pfizer Anti notch-1 antibodies.
BRPI1006897A2 (en) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compounds, compositions and methods for preventing cancer cell metastasis.
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK3241435T3 (en) 2009-07-08 2021-08-23 Kymab Ltd ANIMAL MODELS AND THERAPEUTIC MOLECULES
JO3182B1 (en) * 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
MX2012002651A (en) * 2009-09-01 2012-05-22 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
AR078651A1 (en) * 2009-10-15 2011-11-23 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
MY173390A (en) * 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
EP3279215B1 (en) * 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
KR101688522B1 (en) * 2009-12-15 2016-12-21 삼성전자주식회사 Angiopoietin-2 specific antibodies and uses thereof
JO3274B1 (en) * 2009-12-24 2018-09-16 Regeneron Pharma Human Antibodies To Human Angiopoietin-Like Protein 4
CN101863980B (en) * 2009-12-31 2013-05-08 中国药科大学 Whole human source anti-vascular endothelial cell growth factor receptor 2 single chain antibody
US20110171231A1 (en) * 2010-01-12 2011-07-14 Carlos Bais ANTI-PlGF ANTIBODIES AND METHODS USING SAME
PT2542257T (en) 2010-03-01 2017-10-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
TWI426920B (en) 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-VEGF/anti-ANG-2 antibody
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9707288B2 (en) 2010-07-22 2017-07-18 John W. Schrader Cross-protective pathogen protection, methods and compositions thereof
KR20130100118A (en) 2010-08-03 2013-09-09 아비에 인코포레이티드 Dual variable domain immunoglobulins and uses therof
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2012080926A2 (en) * 2010-12-15 2012-06-21 Wyeth Llc Anti-notch1 antibodies
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US9512220B2 (en) 2011-04-05 2016-12-06 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
JP6038128B2 (en) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
AP2014007588A0 (en) * 2011-09-22 2014-04-30 Amgen Inc CD27L antigen binding proteins
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
DK2760471T3 (en) 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
EP3501536B1 (en) 2011-10-13 2025-12-24 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
MX363351B (en) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Methods for treating vascular leak syndrome and cancer.
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
AR089529A1 (en) 2011-12-30 2014-08-27 Abbvie Inc UNION PROTEINS SPECIFIC DUALS DIRECTED AGAINST IL-13 AND / OR IL-17
KR102063028B1 (en) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. Stabilized formulations containing anti-ang2 antibodies
ES2886123T3 (en) * 2012-01-31 2021-12-16 Regeneron Pharma Anti-asic1 antibodies and their uses
AU2013230750B2 (en) 2012-03-08 2018-02-01 Medimmune, Llc Methods of treatment with Angiopoietin-2 antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
PL2831111T3 (en) 2012-03-30 2019-09-30 Boehringer Ingelheim International Gmbh Ang2-binding molecules
HRP20191690T1 (en) 2012-04-27 2019-12-27 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
SI3495387T1 (en) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecific antibodies against VEGF / against ANG-2 and their use in the treatment of vascular diseases
TR201900694T4 (en) 2012-08-23 2019-02-21 Agensys Inc Antibody drug conjugates (ADC) that bind to 158p1d7 proteins.
EP2890836B1 (en) * 2012-08-31 2019-07-17 The Scripps Research Institute Methods related to modulators of eukaryotic cells
EP2891497B1 (en) * 2012-08-31 2020-07-01 Osaka University Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope
KR101967345B1 (en) 2012-10-18 2019-04-09 삼성전자주식회사 Peptides for inhibition of binding between angiopoietin-2 and integrin and uses thereof
PE20151179A1 (en) 2012-11-01 2015-09-12 Abbvie Inc DUAL ANTI-VEGF / DLL4 VARIABLE DOMAIN IMMUNOGLOBULINS AND USES OF THEM
JP6326066B2 (en) * 2012-12-20 2018-05-16 メディミューン，エルエルシー Liquid antibody formulation with improved aggregation profile
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
MX2015013163A (en) 2013-03-15 2016-04-04 Zyngenia Inc Multivalent and monovalent multispecific complexes and their uses.
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CA2912219C (en) * 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333247B (en) * 2013-05-30 2014-10-08 北京东方百泰生物科技有限公司 Novel monoclonal antibody of VEGFR2 and preparation and application thereof
KR102131371B1 (en) 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 specific antibodies and uses thereof
US9902767B2 (en) 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102146845B1 (en) * 2013-07-30 2020-08-21 삼성전자주식회사 Angiopoietin-2 specific antibodies and uses thereof
KR102196450B1 (en) * 2013-09-17 2020-12-30 삼성전자주식회사 Anticancer composition containing an anti-Ang2 antibody inducing binding to Tie2 receptor
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX371187B (en) 2013-12-06 2020-01-22 Dana Farber Cancer Inst Inc Therapeutic peptides.
KR102206029B1 (en) 2014-01-27 2021-01-20 삼성전자주식회사 Antibody specifically binding to Ang-2 and use thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3116903A2 (en) 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
ES2772817T3 (en) 2014-04-10 2020-07-08 Obi Pharma Inc Tumor-associated carbohydrate antigen binding antibodies, pharmaceutical compositions, and their uses
AR100270A1 (en) * 2014-05-19 2016-09-21 Lilly Co Eli ANTIBODIES ANG2
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
UY36302A (en) 2014-09-15 2016-04-29 Amgen Inc ANTIGENS, BI-SPECIFIC UNION PROTEIN OF THE ANTI-CGRP RECEIVER / PAC1 RECEIVER AND USES OF THE SAME
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
EP3218400A1 (en) * 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-pdgf-b antibodies and methods of use
JP2017537896A (en) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bispecific antibodies and methods for use in ophthalmology
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR20240064733A (en) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
TWI728953B (en) 2015-04-24 2021-06-01 美商安美基公司 Methods for treating or preventing migraine headache
US10857229B2 (en) 2015-04-30 2020-12-08 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
RU2749674C2 (en) * 2015-07-29 2021-06-16 Аллерган, Инк. Antibodies against ang-2 containing only heavy chain
WO2017023780A1 (en) 2015-07-31 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting cd56-positive tumors
CN108135894B (en) 2015-08-20 2021-02-19 卫材R&D管理有限公司 Therapeutic agent for tumor
JP6869987B2 (en) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド Anti-PD-1 antibody and how to use it
HK1255056A1 (en) 2015-09-16 2019-08-02 Ablexis, Llc Anti-cd115 antibodies
CN113713101B (en) 2015-09-23 2023-07-28 视点制药公司 Methods of treating intraocular pressure with activators of TIE-2
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
WO2017083296A1 (en) * 2015-11-09 2017-05-18 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
EP3383435A4 (en) 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED AMINO ACID AND SUGAR REPORTS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS
MY200764A (en) 2015-12-16 2024-01-14 Regeneron Pharma Compositions and methods of manufacturing protein microparticles
CN106939047B (en) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 PD-L1 antibody and preparation method thereof
US10053515B2 (en) * 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
BR112018071307A2 (en) * 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. human cd40 binding agonist antibodies and uses thereof
JP6768847B2 (en) * 2016-06-17 2020-10-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Circulating angiopoietin-2 (Ang-2) for predicting recurrence of atrial fibrillation
KR102379464B1 (en) 2016-06-20 2022-03-29 키맵 리미티드 anti-PD-L1 antibody
EP3484499A4 (en) * 2016-07-14 2020-05-13 Scholar Rock, Inc. ANTI-TGFB ANTIBODIES, METHODS AND USES
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
CN109863171B (en) * 2016-08-23 2023-08-04 免疫医疗有限公司 anti-VEGF-A and anti-ANG 2 antibodies and uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110300599B (en) 2016-12-07 2024-07-02 艾吉纳斯公司 Antibodies and methods of use thereof
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
CN110072528B (en) 2017-02-08 2022-04-26 卫材R&D管理有限公司 Pharmaceutical composition for treating tumor
CN106866824B (en) * 2017-03-06 2020-10-27 哈尔滨医科大学 Fully human monoclonal antibody for resisting DDX5, and preparation method and application thereof
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN109022415B (en) * 2017-06-12 2023-09-15 上海睿智化学研究有限公司 PDGFRβ monoclonal heavy chain antibody hybridoma cells and preparation methods and applications thereof
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
US11674959B2 (en) * 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
CN119264274A (en) 2017-10-12 2025-01-07 免疫苏醒公司 VEGFR-antibody light chain fusion protein
WO2019084307A1 (en) * 2017-10-26 2019-05-02 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
JP2021511782A (en) * 2018-01-31 2021-05-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Stabilized immunoglobulin domain
CN111699004A (en) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 Treatment of ophthalmic disorders
KR102497171B1 (en) 2018-02-20 2023-02-08 기초과학연구원 Anti-angiopoietin-2 Antibodies and Uses Thereof
CN112888709B (en) * 2018-03-30 2024-10-29 优瑞科生物技术公司 Constructs targeting CD22 and their uses
SG11202009629YA (en) 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
CN119033684A (en) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 Antibody formulations
JP7627216B2 (en) * 2018-11-16 2025-02-05 メモリアル スローン ケタリング キャンサー センター Antibodies to mucin-16 and methods of using same - Patents.com
CN111253485A (en) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 Anti-human TIM-3 monoclonal antibody and application thereof
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
JP7564824B2 (en) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド Tie-2 activator targeting Schlemm's canal
WO2020227447A1 (en) * 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors targeting glypican-2
CN112062848B (en) * 2019-06-10 2022-06-17 山东博安生物技术股份有限公司 anti-CD47 monoclonal antibody and application thereof
BR112021026309A2 (en) 2019-06-26 2022-06-07 Ap Biosciences Inc Antibodies for T cell activation
TWI877179B (en) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 Anti-angpt2 antibodies
US20230065377A1 (en) * 2019-08-31 2023-03-02 Vanderbilt University Human antibodies to alphaviruses
CA3190173A1 (en) * 2020-06-22 2021-12-30 Innovent Biologics (Suzhou) Co., Ltd. Anti-ang-2 antibody and use thereof
CN120040592A (en) * 2020-07-31 2025-05-27 百奥泰生物制药股份有限公司 CD47 antibodies and uses thereof
CN116472285A (en) * 2020-08-07 2023-07-21 南京金斯瑞生物科技有限公司 Antibody against human angiopoietin-2 and use thereof
CN114736291B (en) * 2021-01-07 2023-08-11 中国科学院微生物研究所 Humanized monoclonal antibody specifically binding to envelope protein Gn of fever with thrombocytopenia syndrome virus and use thereof
WO2022226539A1 (en) * 2021-04-23 2022-10-27 Immunome, Inc. Methods of administering antibodies against sars-cov-2 spike protein
MX2024001877A (en) 2021-08-10 2024-02-28 Kymab Ltd Treatment of atopic dermatitis.
CN116217732B (en) * 2021-12-06 2026-06-26 重庆精准生物技术有限公司 Bispecific antibodies targeting CD22 and CD19 and their chimeric antigen receptors and applications
CN119630700A (en) * 2022-03-31 2025-03-14 威斯塔解剖学和生物学研究所 Antibodies against human Siglec-9 and their use in immunotherapy
CN116925234B (en) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 AAV vector for encoding anti-VEGF-A and ANG-2 bispecific antibody
WO2024167830A2 (en) * 2023-02-06 2024-08-15 Apeximmune Therapeutics Inc. ANTI-SIRPα ANTIBODIES AND USES THEREOF
WO2025232812A1 (en) * 2024-05-08 2025-11-13 Shanghai Vitalgen Biopharma Co., Ltd. Biomolecule conjugated lipid nanoparticles
CN121628915A (en) * 2024-08-29 2026-03-10 上海泰槿生物技术有限公司 Cells, animals and methods for producing restricted immunoglobulin light chain repertoires
CN120058951B (en) * 2025-02-27 2025-11-04 郑州伊美诺生物技术有限公司 Monoclonal antibodies against aminoacyl-tRNA synthetases and uses thereof
CN120446482B (en) * 2025-07-10 2025-09-19 杭州华得森生物技术有限公司 Microfluidic chip PSMA prostate cancer circulating tumor cell immune enrichment detection kit and preparation method
CN121537523B (en) * 2026-01-19 2026-04-21 武汉睿欣和生物科技有限公司 PGI monoclonal antibody combination for pepsinogen I detection and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075323A1 (en) * 1999-06-07 2000-12-14 Immunex Corporation Tek antagonists
WO2003030833A2 (en) * 2001-10-11 2003-04-17 Amgen Inc. Angiopoietin-2 specific binding agents

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1A1 (en) 1921-03-25 1924-09-15 А.М. Настюков Continuous sulphide furnace
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (en) 1982-01-06 1983-07-13 Nec Corp Data processor
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (en) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Means and product for the diagnosis and therapy of tumors and for the treatment of weaknesses in cellular and humoral immune defense
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
FR2664073A1 (en) 1990-06-29 1992-01-03 Thomson Csf MEANS FOR MARKING OBJECTS, METHOD FOR PRODUCING THE SAME, AND DEVICE FOR READING.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ES2301158T3 (en) 1992-07-24 2008-06-16 Amgen Fremont Inc. XENOGENIC ANTIBODY PRODUCTION.
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) * 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
CA2216963C (en) 1995-04-06 2010-06-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19525542A1 (en) 1995-07-13 1997-01-16 Mann & Hummel Filter Heating device
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimeric animal and method for producing the same
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
BR9912053A (en) 1998-07-13 2001-04-03 Univ Texas Cancer treatment processes using therapeutic conjugates that bind to aminophospholipids
EP1096955B9 (en) 1998-07-13 2006-07-05 Board of Regents, The University of Texas System Uses of antibodies to aminophospholipids for cancer treatment
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (en) 1999-02-10 2010-10-15 Astrazeneca Ab Quinazoline derivatives as inhibitors of angiogenesis
NZ514434A (en) 1999-03-26 2003-11-28 Univ California Modulation of vascular permeability by means of TIE2 receptor activators
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6521424B2 (en) * 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1130094A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
CA2376361A1 (en) 1999-08-19 2001-03-01 Genset S.A. Prostate cancer-related gene 3 (pg-3) and biallelic markers thereof
PT1244647E (en) 1999-11-05 2006-10-31 Astrazeneca Ab QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS
AU2001252945A1 (en) 2000-03-24 2001-10-08 Corixa Corporation Compositions and methods for therapy and diagnosis of colon cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
BR0111230A (en) 2000-05-31 2003-06-10 Astrazeneca Ab Compound, and, use and process for the preparation thereof
EE200300015A (en) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Colchinol derivatives as inhibitors of angiogenesis
KR20030014425A (en) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 Colchinol derivatives as vascular damaging agents
US7642278B2 (en) 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20030175760A1 (en) 2001-12-03 2003-09-18 Walker Wynn L. Discovery of therapeutic products
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
DE102004062018B4 (en) 2004-12-23 2018-10-11 Robert Bosch Gmbh Method for operating an internal combustion engine
EA015992B1 (en) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Stabilized antibody and multivalent antibinding molecule based thereon, methods for making thereof and use such stabilized antibody
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
JP4616237B2 (en) 2006-11-07 2011-01-19 日本電信電話株式会社 Method for forming silicon compound thin film
KR101136303B1 (en) 2008-01-28 2012-04-24 리서치 인 모션 리미티드 Method and system for providing session initiation protocol request content
US8507656B2 (en) * 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
JO3182B1 (en) * 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
JP6071725B2 (en) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 Driving force control device for electric vehicles
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075323A1 (en) * 1999-06-07 2000-12-14 Immunex Corporation Tek antagonists
WO2003030833A2 (en) * 2001-10-11 2003-04-17 Amgen Inc. Angiopoietin-2 specific binding agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAI M ET AL: "Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 309, no. 4, 3 October 2003 (2003-10-03), pages 946 - 951, XP004455833, ISSN: 0006-291X *
FIEDLER ULRIKE ET AL: "Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 17 JAN 2003, vol. 278, no. 3, 17 January 2003 (2003-01-17), pages 1721 - 1727, XP002383517, ISSN: 0021-9258 *
LIN PENGNIAN ET AL: "Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 100, no. 8, 1997, pages 2072 - 2078, XP002294946, ISSN: 0021-9738 *
MAISONPIERRE P C ET AL: "ANGIOPOIETIN-2, A NATURAL ANTAGONIST FOR TIE2 THAT DISRUPTS IN VIVO ANGIOGENESIS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 277, 4 July 1997 (1997-07-04), pages 55 - 60, XP002046280, ISSN: 0036-8075 *
OLINER J ET AL: "Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2", CANCER CELL, XX, US, vol. 6, no. 5, November 2004 (2004-11-01), pages 507 - 516, XP002348738, ISSN: 1535-6108 *
ROBINSON CANDY S ET AL: "The effects of Angiopoietin-2 and neutralizing anti-TIE-2 antibody on microvessel growth, branching, and regression in the ex vivo rat aortic ring explant model of angiogenesis", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, March 2001 (2001-03-01), & 92ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; NEW ORLEANS, LA, USA; MARCH 24-28, 2001, pages 2, XP001208033, ISSN: 0197-016X *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF
US10927163B2 (en) 2007-12-21 2021-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US10138293B2 (en) 2007-12-21 2018-11-27 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US11993642B2 (en) 2009-04-07 2024-05-28 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US10640555B2 (en) 2009-06-16 2020-05-05 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US11673945B2 (en) 2009-06-16 2023-06-13 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US9982036B2 (en) 2011-02-28 2018-05-29 Hoffmann-La Roche Inc. Dual FC antigen binding proteins
US10793621B2 (en) 2011-02-28 2020-10-06 Hoffmann-La Roche Inc. Nucleic acid encoding dual Fc antigen binding proteins
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US11407836B2 (en) 2012-06-27 2022-08-09 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US12698332B2 (en) 2012-06-27 2026-08-04 Hoffmann-La Roche Inc. Method for selection and production of multi-specific targeting entities containing at least an antibody fc-region and an antigen binding peptide and uses thereof
US9518131B2 (en) 2013-04-02 2016-12-13 Miltenyi Biotech Gmbh Generating metal ion binding proteins
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
US11999801B2 (en) 2014-12-03 2024-06-04 Hoffman-La Roche Inc. Multispecific antibodies

Also Published As

Publication number Publication date
US20130171160A1 (en) 2013-07-04
US10066011B2 (en) 2018-09-04
JP2008523841A (en) 2008-07-10
EP1838733B1 (en) 2011-08-24
US20080267971A1 (en) 2008-10-30
SI1838733T1 (en) 2011-12-30
HK1217713A1 (en) 2017-01-20
ATE521638T1 (en) 2011-09-15
ZA200705695B (en) 2009-02-25
WO2006068953A2 (en) 2006-06-29
CN101128483A (en) 2008-02-20
UY29288A1 (en) 2006-07-31
JP5642042B2 (en) 2014-12-17
NZ556029A (en) 2010-04-30
HRP20110859T1 (en) 2011-12-31
EP3699191A1 (en) 2020-08-26
HK1109409A1 (en) 2008-06-06
CA2595610C (en) 2013-03-05
EP2284194A1 (en) 2011-02-16
US7973140B2 (en) 2011-07-05
DK1838733T3 (en) 2011-11-28
NO20073192L (en) 2007-09-06
CN101128483B (en) 2015-06-03
AU2005319382A1 (en) 2006-06-29
CY1112909T1 (en) 2016-04-13
TW200634027A (en) 2006-10-01
PL1838733T3 (en) 2012-02-29
US20150125455A1 (en) 2015-05-07
CA2595610A1 (en) 2006-06-29
BRPI0519596A2 (en) 2009-03-24
CN105085678A (en) 2015-11-25
MX2007007484A (en) 2007-07-20
BRPI0519596B1 (en) 2022-01-18
US20060246071A1 (en) 2006-11-02
KR101017301B1 (en) 2011-02-28
US8834880B2 (en) 2014-09-16
RU2007127842A (en) 2009-01-27
ES2371083T3 (en) 2011-12-27
AR052065A1 (en) 2007-02-28
AU2005319382B2 (en) 2011-04-07
PT1838733E (en) 2011-12-13
RS52036B (en) 2012-04-30
US20120052073A1 (en) 2012-03-01
JP2012050455A (en) 2012-03-15
CN105085678B (en) 2019-05-07
KR20070116217A (en) 2007-12-07
RU2394839C2 (en) 2010-07-20
JP4884395B2 (en) 2012-02-29
EP1838733A2 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
MX2007007484A (en) Antibodies directed to angiopoietin-2 and uses thereof.
WO2006081139A3 (en) Antibodies against interleukin-1 beta
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
WO2005118635A3 (en) Anti-cd3 antibodies and methods of use thereof
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
WO2004050683A3 (en) Antibodies directed to tumor necrosis factor and uses thereof
WO2007109307A3 (en) Antibodies directed to angiopoietin-like protein 4 and uses thereof
WO2006052591A3 (en) Anti-properdin antibodies, and methods for making and using same
WO2004050850A3 (en) Antibodies directed to phospholipase a2 and uses thereof
WO2007070432A3 (en) Binding proteins specific for insulin-like growth factors and uses thereof
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
WO2004084823A3 (en) Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
WO2006104978A3 (en) Antibodies against the tenascin major antigens
WO2004016769A3 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
WO2006055638A3 (en) Fully human monoclonal antibodies to il-13
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
WO2006039258A3 (en) Human antibodies against parathyroid hormone
WO2008009960A3 (en) Anti-testosterone antibodies
WO2006055704A3 (en) Antibodies directed to ten-m proteins and uses thereof
WO2007065037A3 (en) Antibodies against mmp-13 (collagenase-3) and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005319382

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2595610

Country of ref document: CA

Ref document number: 184066

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/007484

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007548333

Country of ref document: JP

Ref document number: 556029

Country of ref document: NZ

Ref document number: 12007501323

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2478/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005319382

Country of ref document: AU

Date of ref document: 20051219

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005319382

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005854387

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007127842

Country of ref document: RU

Ref document number: 07074694

Country of ref document: CO

Ref document number: 1020077016981

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580048270.9

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005854387

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11793720

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0519596

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: P-2011/0477

Country of ref document: RS